ArticlePathology oncology research : POR2004
Human osteosarcoma xenografts and their sensitivity to chemotherapy.
Article in Pathology oncology research : POR, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- The Osteosarcoma Tumor Microenvironment: From Cellular Interactions to Advanced Preclinical Models.Cancers · 2026Review
- Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine.Biomolecules · 2023Review
- Review
- Review
- Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- DNA direct reversal repair and alkylating agent drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings.Histology and histopathology · 2020Article
- Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020Review
- Influx rate ofEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.Scientific reports · 2019Article
- Patient-derived xenograft models in musculoskeletal malignancies.Journal of translational medicine · 2018Review
- Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Molecular mechanisms of chemoresistance in osteosarcoma (Review).Oncology letters · 2014Article
- Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.Expert opinion on drug discovery · 2013Review
- Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.Cancer letters · 2011Article
- The significance of MGMT protein detection in evaluation of osteosarcoma necrosis rate after cisplatin chemotherapy.Bosnian journal of basic medical sciences · 2011Article
- Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.Oncogene · 2009Article
- Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi.European journal of nuclear medicine and molecular imaging · 2007Article
- Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the increased survival rates of osteosarcoma patients attributed to adjuvant chemotherapy, at least one third of the patients still die due to their disease. Further improvements in the management of osteosarcoma may rely on a more individualised treatment strategy, as well as on the introduction of new drugs. To aid in the preclinical evaluation of new candidate substances against osteosarcoma, we have established 11 human osteosarcoma xenograft lines and characterised them with regard to response to five different reference drugs. Doxorubicin, cisplatin methotrexate, ifosfamide and lomustine were effective in 3/11, 3/11, 1/10, 5/11 and 4/11 of the xenografts, respectively. Five xenografts were resistant to all compounds tested. We also assessed the mRNA expression levels of the xenografts for the O(6)-Methylguanine DNA Methyltransferase (MGMT), DNA topoisomerase II- (Topo II)-alpha, Gluthathione-S-transferase (GST)-pi, Multidrug-resistance related protein (MRP) 1 and Multidrug-resistance (MDR) 1 genes. There was an inverse correlation between the transcript levels of GST-pi and doxorubicin growth inhibition (r=-0.66; p<0.05), and between the transcript levels of MGMT and the effect of lomustine (r=-0.72; p<0.01), whereas the expression of MRP1 and cisplatin growth inhibition was positively correlated (r=0.82; p<0.005). This panel of xenografts should constitute a good tool for pharmacological and molecular studies in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.